We are the largest privately owned independent company in the world in plasma fractionation. Our medicines consist of life-saving human proteins produced from blood plasma or using recombinant DNA technology.
We supply immunoglobulins to patients via the National Blood Supply System.
We develop and manufacture medicines for patients in three treatment areas: haematology, IgG immunotherapy and intensive care.
We are located in more than 31 countries and our medicines help people in 118 countries around the world. We have seven R&D and six manufacturing sites in Europe and North America.
Here you can choose your preferences. Click on the different categories to find out more. Please note that blocking some of the cookies may impact you web experience.
Without this cookies, the website cannot perform basic functions. They may be set automatically when pages load, or as a result of a user request that cannot be fulfilled without the use of the cookie.
These cookies allow our website to remember choices you make while browsing. For instance, we may store your geographic location in a cookie to ensure that we show you our website localized for your area.
We use Google Analytics to collect information about how our visitors use and navigate our site. We use this information to report and analyse the usage of the site with the intention to improve the usage of the homepage for visitors.
Find more information in our Data Privacy Statement.
You are now leaving Octapharma.com.au
The website or information you are about to access may not comply with Australian regulatory requirements. For Australian relevant information please refer to or contact Octapharma Australia.
To return to the prior page, please select cancel.
To continue to the offsite link, please select continue.